GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
AU633698B2
(en)
|
1990-01-12 |
1993-02-04 |
Amgen Fremont Inc. |
Generation of xenogeneic antibodies
|
EP0546091B1
(en)
|
1990-08-29 |
2007-01-24 |
Pharming Intellectual Property BV |
Homologous recombination in mammalian cells
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
US6130364A
(en)
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
KR101004174B1
(ko)
|
1995-06-29 |
2010-12-24 |
임뮤넥스 코포레이션 |
세포소멸을 유도하는 시토킨
|
EP1007082B1
(en)
|
1997-01-15 |
2006-10-18 |
Phoenix Pharmacologics, Inc. |
Modified tumor necrosis factor
|
ATE362982T1
(de)
|
1997-01-28 |
2007-06-15 |
Human Genome Sciences Inc |
ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
|
US6072047A
(en)
|
1997-02-13 |
2000-06-06 |
Immunex Corporation |
Receptor that binds trail
|
WO1999000423A1
(en)
|
1997-06-26 |
1999-01-07 |
Immunex Corporation |
Protein that binds trail
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6329148B1
(en)
|
1999-02-16 |
2001-12-11 |
The Board Of Trustees Of The Leland Stanford University |
Combined therapy of diterpenoid triepoxides and death domain receptor ligands for synergistic killing of tumor cells
|
US7550143B2
(en)
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
SI1180121T1
(en)
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US7160924B2
(en)
|
2002-07-19 |
2007-01-09 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
CA2386002A1
(en)
|
1999-09-30 |
2001-04-05 |
The Trustees Of The University Of Pennsylvania |
Trail: an inhibitor of autoimmune inflammation and cell cycle progression
|
IL136156A0
(en)
|
2000-05-16 |
2001-05-20 |
Compugen Ltd |
Sequences of trail variants
|
US20040005314A1
(en)
|
2001-07-27 |
2004-01-08 |
Enrique Escandon |
Apo-2l receptor agonist and cpt-11 synergism
|
KR100396983B1
(ko)
|
2000-07-29 |
2003-09-02 |
이강춘 |
고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
|
US20020058029A1
(en)
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
KR20020056565A
(ko)
|
2000-12-29 |
2002-07-10 |
황규언 |
인간유래 세포 소멸 인자와 그 수용체의 결합체인TRAIL-sDR5 결합체의 결정화에 의한 3차원 구조및 TRAIL 결실 돌연변이 단백질
|
US20020169123A1
(en)
|
2001-02-27 |
2002-11-14 |
The Trustees Of The University Of Pennsylvania |
Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
|
CN1278675C
(zh)
|
2001-07-10 |
2006-10-11 |
佳能株式会社 |
含聚羟基烷醇酸酯的粒状体及其制备方法
|
DE10144252A1
(de)
|
2001-08-31 |
2003-03-27 |
Fraunhofer Ges Forschung |
Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
|
WO2003029420A2
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
US6908963B2
(en)
|
2001-10-09 |
2005-06-21 |
Nektar Therapeutics Al, Corporation |
Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
JP4574350B2
(ja)
|
2002-06-24 |
2010-11-04 |
ジェネンテック, インコーポレイテッド |
Apo−2リガンド/trail変異体とその使用法
|
WO2004022004A2
(en)
|
2002-09-06 |
2004-03-18 |
Bayer Pharmaceuticals Corporation |
Modified glp-1 receptor agonists and their pharmacological methods of use
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
EP1558631A4
(en)
|
2002-10-30 |
2006-10-04 |
Pfizer Prod Inc |
METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER OF PETS
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
DE602004019701D1
(de)
|
2003-05-09 |
2009-04-09 |
Genentech Inc |
Peptide welche an Apo2L (Trail) Rezeptoren binden und Verwendungen davon
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
US7795404B1
(en)
|
2003-08-08 |
2010-09-14 |
Five Prime Therapeutics, Inc. |
Human soluble notch receptor ligands
|
GB0328261D0
(en)
|
2003-12-05 |
2004-01-07 |
Univ Groningen |
Improved cytokine design
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
US8003111B2
(en)
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
AU2005264993A1
(en)
|
2004-06-18 |
2006-01-26 |
Genentech, Inc. |
Use of Apo2L receptor agonists and NK cells or NK cell activators
|
WO2006010057A2
(en)
|
2004-07-08 |
2006-01-26 |
Amgen Inc. |
Therapeutic peptides
|
US20060046961A1
(en)
|
2004-09-02 |
2006-03-02 |
Mckay William F |
Controlled and directed local delivery of anti-inflammatory compositions
|
RU2007112929A
(ru)
|
2004-09-08 |
2008-10-20 |
Дженентек, Инк. (Us) |
Способы применения лигандов рецептора смерти и антител к cd20
|
WO2006042848A2
(en)
|
2004-10-18 |
2006-04-27 |
Novo Nordisk A/S |
Growth hormone conjugates
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
US20060188498A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
EP1695717A1
(en)
|
2005-02-23 |
2006-08-30 |
Ludwig-Maximilians-Universität |
Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
|
US20060228352A1
(en)
|
2005-02-24 |
2006-10-12 |
Schoenberger Stephen P |
TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
|
CA2604032C
(en)
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
AU2006232310B9
(en)
|
2005-04-06 |
2011-07-21 |
Ibc Pharmaceuticals, Inc. |
Improved stably tethered structures of defined compositions with multiple functions or binding specificities
|
EP1745802A1
(en)
|
2005-07-20 |
2007-01-24 |
Kreatech Biotechnology B.V. |
Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
|
CA2607056C
(en)
|
2005-10-19 |
2015-11-24 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
GB0524316D0
(en)
|
2005-11-29 |
2006-01-04 |
Medical Res Council |
Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
|
EP1968644B1
(en)
|
2005-12-16 |
2012-06-27 |
Nektar Therapeutics |
Polymer conjugates of glp-1
|
CA2636424A1
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
|
KR100784485B1
(ko)
|
2006-01-18 |
2007-12-11 |
한국과학기술연구원 |
생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
|
WO2007102690A1
(en)
|
2006-03-06 |
2007-09-13 |
Postech Foundation |
Vector including the codon-optimized dna cassette for producing secretory recombinant dodecamer trail
|
KR100746962B1
(ko)
|
2006-04-04 |
2007-08-07 |
한국과학기술연구원 |
온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
CN101074261A
(zh)
*
|
2006-04-30 |
2007-11-21 |
北京同为时代生物技术有限公司 |
Trail受体1和/或trail受体2特异性抗体及其应用
|
US8080248B2
(en)
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
KR100886783B1
(ko)
|
2006-06-12 |
2009-03-04 |
성균관대학교산학협력단 |
N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
|
BRPI0712629C1
(pt)
|
2006-06-20 |
2021-07-27 |
Genentech Inc |
método para a detecção da apoptose e método para a identificação de uma célula de câncer humano
|
RU2009101783A
(ru)
|
2006-06-21 |
2010-07-27 |
Апогеникс Гмбх (De) |
Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека
|
WO2008088582A2
(en)
|
2006-08-04 |
2008-07-24 |
Mayo Foundation For Medical Education And Research |
Methods and materials related to trail isoforms
|
AU2007292295B2
(en)
|
2006-09-06 |
2013-06-06 |
Immunoforge Co., Ltd. |
Fusion peptide therapeutic compositions
|
WO2008120832A1
(en)
|
2007-03-30 |
2008-10-09 |
Industry-Academic Cooperation Foundation, Yonsei University |
Human neural stem cell secreting a smac, preparation method and use thereof
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
KR100968591B1
(ko)
|
2007-06-14 |
2010-07-08 |
한국과학기술연구원 |
약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
|
BRPI0814645A2
(pt)
|
2007-07-25 |
2015-01-27 |
Alexion Pharma Inc |
Métodos e composições para tratar de doença autoimune.
|
JPWO2009020094A1
(ja)
|
2007-08-09 |
2010-11-04 |
第一三共株式会社 |
疎水性分子で修飾した抗体
|
WO2009055014A2
(en)
|
2007-10-23 |
2009-04-30 |
Nektar Therapeutics Al, Corporation |
Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
|
AU2008319298B2
(en)
|
2007-10-31 |
2014-07-31 |
Medimmune, Llc |
Protein scaffolds
|
GB0723059D0
(en)
|
2007-11-23 |
2008-01-02 |
Nat Univ Ireland |
Improved cytokine design
|
US20090203671A1
(en)
|
2007-11-27 |
2009-08-13 |
Abbott Laboratories |
Method of treating cancer
|
GB0724532D0
(en)
|
2007-12-17 |
2008-01-30 |
Nat Univ Ireland |
Trail variants for treating cancer
|
JP5699362B2
(ja)
|
2008-04-10 |
2015-04-08 |
アイビーシー ファーマスーティカルズ,インコーポレイテッド |
薬物動態が改善された四量体サイトカインをドック・アンド・ロック(dnl)技術により調製するためのモジュール法
|
WO2009140469A2
(en)
|
2008-05-14 |
2009-11-19 |
Genentech, Inc. |
Methods of using apo2l/trail to treat cancer
|
US20100068302A1
(en)
|
2008-09-17 |
2010-03-18 |
Traslational Cancer Drugs Pharma, S.L. |
Methods and compositions for the treatment of cancer
|
GB0818649D0
(en)
|
2008-10-10 |
2008-11-19 |
Nat Univ Ireland |
Treatment of proliferative disorders with trail
|
EP2379585A2
(en)
|
2008-10-10 |
2011-10-26 |
Anaphore, Inc. |
Polypeptides that bind trail-ri and trail-r2
|
EP2393828B1
(en)
|
2009-02-03 |
2016-10-12 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
CN102448494B
(zh)
|
2009-02-13 |
2016-02-03 |
免疫医疗公司 |
具有胞内可裂解的键的免疫共轭物
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
CA2772572A1
(en)
|
2009-08-31 |
2011-03-03 |
Ibc Pharmaceuticals, Inc. |
Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
|
WO2011079293A1
(en)
|
2009-12-23 |
2011-06-30 |
Ambrx, Inc |
Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
|
EP2519260A2
(en)
|
2009-12-31 |
2012-11-07 |
Deutsches Krebsforschungszentrum |
Novel modulators of trail signalling
|
WO2011106707A2
(en)
*
|
2010-02-26 |
2011-09-01 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to dr3
|
BR112012026003B1
(pt)
|
2010-04-13 |
2022-03-15 |
Medimmune, Llc |
Estrutura multimérica recombinante específica trail r2, seu uso, bem como composição
|
US8461311B2
(en)
|
2010-06-08 |
2013-06-11 |
Washington University |
TRAIL trimers, methods and uses therefor
|
KR101209266B1
(ko)
|
2010-06-30 |
2012-12-06 |
한국과학기술연구원 |
생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
|
WO2012018616A2
(en)
|
2010-07-26 |
2012-02-09 |
Anaphore, Inc. |
Polypeptides that bind trail-r1 and trail-r2
|
KR101814852B1
(ko)
|
2010-10-29 |
2018-01-04 |
다이이찌 산쿄 가부시키가이샤 |
신규 항 dr5 항체
|
EP2468764A1
(en)
|
2010-12-24 |
2012-06-27 |
Rijksuniversiteit te Groningen |
TNF family ligand variants
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
CA2828405A1
(en)
|
2011-02-28 |
2012-09-07 |
Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale |
Apoptosis-inducing molecules and uses therefor
|
JP2014510080A
(ja)
|
2011-03-09 |
2014-04-24 |
セントローズ, エルエルシー |
細胞外標的化薬物複合体
|
DK3138581T3
(en)
|
2011-03-17 |
2019-04-15 |
Univ Birmingham |
REDIRECTED IMMUNTERY
|
US20130101553A1
(en)
|
2011-04-18 |
2013-04-25 |
The Regents Of The University Of California |
Inducing inactivation of fibrogenic myofibroblasts
|
JP6132833B2
(ja)
|
2011-04-29 |
2017-05-24 |
ザ ペン ステイト リサーチ ファンデーション |
抗癌療法としての正常細胞および腫瘍細胞の小分子trail遺伝子誘導
|
US20140178398A1
(en)
|
2011-05-03 |
2014-06-26 |
Genentech, Inc |
Vascular disruption agents and uses thereof
|
FI20115640A0
(fi)
|
2011-06-22 |
2011-06-22 |
Turun Yliopisto |
Yhdistelmähoito
|
US8586020B2
(en)
|
2011-06-30 |
2013-11-19 |
Korea Institute Of Science And Technology |
Poly(organophosphazene) composition for biomaterials
|
PL2717917T3
(pl)
|
2011-07-05 |
2016-12-30 |
|
Koniugaty p97 - przeciwciało
|
US20130150566A1
(en)
|
2011-07-06 |
2013-06-13 |
Targetpharma Laboratories (Changzhou) Co., Ltd |
Tumor-targeted tnf-related apoptosis-inducing ligand's variant and the application thereof
|
CN102898526A
(zh)
|
2011-07-28 |
2013-01-30 |
山东先声麦得津生物制药有限公司 |
一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
CA2867631C
(en)
|
2012-03-28 |
2019-06-11 |
Amgen Inc. |
Dr5 receptor agonist combinations
|
WO2013156054A1
(en)
|
2012-04-16 |
2013-10-24 |
Universität Stuttgart |
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
|
EP3473708B1
(en)
|
2012-07-24 |
2021-01-27 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
US20150038511A1
(en)
|
2012-08-09 |
2015-02-05 |
Celgene Corporation |
Treatment of immune-related and inflammatory diseases
|
CA2883356A1
(en)
|
2012-08-30 |
2014-03-06 |
Turun Yliopisto |
Method of selecting individualized brain cancer therapy
|
US9605074B2
(en)
|
2012-08-30 |
2017-03-28 |
The General Hospital Corporation |
Multifunctional nanobodies for treating cancer
|
EP3916013A1
(en)
|
2012-09-20 |
2021-12-01 |
MorphoSys AG |
Treatment for rheumatoid arthritis with anti-gm-csf antibody
|
US20140134647A1
(en)
|
2012-11-01 |
2014-05-15 |
La Jolla Institute For Allergy And Immunology |
Novel crystal structure and ligand binding sites of trail receptor
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
US20150301058A1
(en)
|
2012-11-26 |
2015-10-22 |
Caris Science, Inc. |
Biomarker compositions and methods
|
WO2014121093A1
(en)
*
|
2013-01-31 |
2014-08-07 |
Thomas Jefferson University |
Fusion proteins that facilitate cancer cell destruction
|
SG11201506366SA
(en)
|
2013-02-13 |
2015-09-29 |
Agency Science Tech & Res |
A Polymeric System for Release of an Active Agent
|
WO2015010615A1
(zh)
|
2013-07-23 |
2015-01-29 |
四川大学华西医院 |
一种重组trail蛋白及其制备方法和用途
|
EP3041846B1
(en)
|
2013-09-02 |
2018-11-07 |
Hangzhou Dac Biotech Co., Ltd |
Novel cytotoxic agents for conjugation of drugs to cell binding molecule
|
WO2015037000A1
(en)
|
2013-09-11 |
2015-03-19 |
Compugen Ltd |
Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
|
PL222795B1
(pl)
|
2013-12-22 |
2016-09-30 |
Univ Warszawski |
Rekombinowane białko fuzyjne ProSTAT do zastosowania w leczeniu
|
WO2015127685A1
(en)
|
2014-02-28 |
2015-09-03 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
US11299528B2
(en)
|
2014-03-11 |
2022-04-12 |
D&D Pharmatech Inc. |
Long acting TRAIL receptor agonists for treatment of autoimmune diseases
|
US9901620B2
(en)
*
|
2014-04-21 |
2018-02-27 |
Theraly Pharmaceuticals, Inc. |
Trail receptor agonists for treatment of fibrotic disease
|
LT3145530T
(lt)
*
|
2014-04-21 |
2021-07-12 |
D&D Pharmatech Inc. |
Trail receptoriaus agonistai, skirti fibrozinių ligų gydymui
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|